- K-V: FDA will approve Gestiva by PDUFA date
- GPhA responds to potential OGD funding cuts; announces exit of Gordon Johnston
- Legislation introduced to restore OTCs as qualified FSA/HSA reimbursements
- Merck's hepatitis C drug granted priority review by FDA
- New alliance will crack down on adulterated products touting dietary supplement claims
WASHINGTON — The House of Representatives will be debating H.R. 5651 Wednesday afternoon — a bill that, if passed, will reauthorize the Prescription Drug User Fee Act.
The Senate passed a similar measure last week by a vote of 96-to-1 with three senators not voting.
John Gay, VP government affairs for the Consumer Healthcare Products Association, noted that swift action is needed to ensure the reauthorization is finalized before the current authorization expires at the end of September. “We encourage House leadership to act soon to reconcile this legislation with the version passed by the Senate, so that this crucial bill is enacted before autumn,” Gay said. CHPA sent a letter to the leaders of the U.S. House of Representatives, urging the swift reauthorization of the bill earlier Wednesday.